EE+ POEM Archive
Tirzepatide is at least as effective as dulaglutide at reducing cardiovascular events in patients with Type 2 diabetes (SURPASS-CVOT)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Tirzepatide Is at Least as Effective as Dulaglutide at Reducing Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)." EE+ POEM Archive, John Wiley & Sons, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377586/all/Tirzepatide_is_at_least_as_effective_as_dulaglutide_at_reducing_cardiovascular_events_in_patients_with_Type_2_diabetes__SURPASS_CVOT_.
Tirzepatide is at least as effective as dulaglutide at reducing cardiovascular events in patients with Type 2 diabetes (SURPASS-CVOT). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377586/all/Tirzepatide_is_at_least_as_effective_as_dulaglutide_at_reducing_cardiovascular_events_in_patients_with_Type_2_diabetes__SURPASS_CVOT_. Accessed March 13, 2026.
Tirzepatide is at least as effective as dulaglutide at reducing cardiovascular events in patients with Type 2 diabetes (SURPASS-CVOT). (2026). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377586/all/Tirzepatide_is_at_least_as_effective_as_dulaglutide_at_reducing_cardiovascular_events_in_patients_with_Type_2_diabetes__SURPASS_CVOT_
Tirzepatide Is at Least as Effective as Dulaglutide at Reducing Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2026. [cited 2026 March 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377586/all/Tirzepatide_is_at_least_as_effective_as_dulaglutide_at_reducing_cardiovascular_events_in_patients_with_Type_2_diabetes__SURPASS_CVOT_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tirzepatide is at least as effective as dulaglutide at reducing cardiovascular events in patients with Type 2 diabetes (SURPASS-CVOT)
ID - 3377586
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377586/all/Tirzepatide_is_at_least_as_effective_as_dulaglutide_at_reducing_cardiovascular_events_in_patients_with_Type_2_diabetes__SURPASS_CVOT_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
